MedTrace Logo

Effect of Preoperative Dexamethasone in Preventing Spinal Hypotension In Patients Undergoing Elective Caesarian Section

NCT07761585 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-08-12

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether giving a single dose of intravenous dexamethasone before spinal anesthesia can help prevent low blood pressure (spinal hypotension) in pregnant women undergoing elective cesarean section. Low blood pressure after spinal anesthesia is common and may cause nausea, vomiting, dizziness, and reduced blood flow to the baby. If dexamethasone works, it may help maintain stable blood pressure during surgery, reduce the need for medicines used to treat low blood pressure, and improve the safety and comfort of both the mother and baby.

The main questions it aims to answer are:

* Does preoperative intravenous dexamethasone reduce the occurrence of spinal hypotension after spinal anesthesia?
* Does dexamethasone reduce the amount of vasopressor medicine needed to treat low blood pressure during surgery?

Researchers will compare 8 mg intravenous dexamethasone with normal saline (placebo) to determine whether dexamethasone is more effective in preventing spinal hypotension during elective cesarean section.

Participants will:

* Receive either intravenous dexamethasone or a placebo before spinal anesthesia.
* Undergo elective cesarean section under spinal anesthesia.
* Have their blood pressure monitored during surgery.
* Receive standard treatment if their blood pressure becomes too low.
* Have their blood pressure measurements and the need for blood pressure-raising medicines recorded to compare the effects of the two treatments.

Conditions

  • Caesarian Section

Interventions

DRUG

Dexamethasone

Dexamethasone

Sponsors & Collaborators

  • Liaquat National Hospital & Medical College

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2026-07-21
Completion
2026-07-21

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07761585 on ClinicalTrials.gov